TajikistanTuberculosis profile
Population  2016 8.7 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.52 (0.4–0.66) 6 (4.6–7.6)
Mortality (HIV+TB only) 0.051 (0.036–0.069) 0.58 (0.41–0.79)
Incidence  (includes HIV+TB) 7.5 (5.7–9.4) 85 (65–108)
Incidence (HIV+TB only) 0.25 (0.16–0.35) 2.8 (1.8–4)
Incidence (MDR/RR-TB)** 2.6 (2.1–3.1) 30 (24–36)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.39 (0.29–0.48) 3 (2.2–3.7) 3.4 (2.5–4.2)
Males 0.44 (0.33–0.55) 3.7 (2.7–4.6) 4.1 (3.1–5.1)
Total 0.83 (0.62–1) 6.6 (5–8.3) 7.5 (5.7–9.4)
TB case notifications, 2016  
Total cases notified 6 241
Total new and relapse 5 965
          - % tested with rapid diagnostics at time of diagnosis 73%
          - % with known HIV status 94%
          - % pulmonary 73%
          - % bacteriologically confirmed among pulmonary 69%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.08 (0.05–0.11)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 201 3%
          - on antiretroviral therapy 182 91%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 200
(1 200–1 300)
Estimated % of TB cases with MDR/RR-TB 22% (21–24) 45% (40–50)  
% notified tested for rifampicin resistance 49% 60% 3 188
MDR/RR-TB cases tested for resistance to second-line drugs   697
Laboratory-confirmed cases MDR/RR-TB: 748, XDR-TB: 445
Patients started on treatment **** MDR/RR-TB: 700, XDR-TB: 43
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 89% 5 298
Previously treated cases, excluding relapse, registered in 2015 80% 286
HIV-positive TB cases registered in 2015 72% 131
MDR/RR-TB cases started on second-line treatment in 2014 50% 804
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 57%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (94–100)
TB financing, 2017  
National TB budget (US$ millions) 25
Funding source: 23% domestic, 60% international, 17% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-16 Data: www.who.int/tb/data